Last updated on April 2017

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis


Brief description of study

This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).

Clinical Study Identifier: NCT02951195

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Medical Information

Birmingham, AL United States
  Connect »

Medical Information

La Jolla, CA United States
  Connect »

Medical Information

Los Angeles, CA United States
  Connect »

Medical Information

Orlando, FL United States
  Connect »

Medical Information

Chicago, IL United States
  Connect »

Medical Information

Peoria, IL United States
  Connect »

Medical Information

Saint Louis, MO United States
  Connect »

Medical Information

Chapel Hill, NC United States
  Connect »

Medical Information

Akron, OH United States
  Connect »

Medical Information

Cleveland, OH United States
  Connect »

Medical Information

Portland, OR United States
  Connect »

Medical Information

Philadelphia, PA United States
  Connect »

Medical Information

Charleston, SC United States
  Connect »

Medical Information

Fort Worth, TX United States
  Connect »

Medical Information

Houston, TX United States
  Connect »

Medical Information

Madison, WI United States
  Connect »